Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00258479 |
Nicotine is one of the most widely abused substances in the United States. Nicotine replacement therapy (NRT) is currently an effective treatment for nicotine dependence; however, even with NRT most people fail at quitting smoking after their first attempt. Modafinil is a promising drug that may be useful in treating nicotine dependent individuals. The purpose of this study is to evaluate the safety of the combination of modafinil and NRT in treating nicotine dependent adolescent smokers.
Condition | Intervention | Phase |
---|---|---|
Tobacco Use Disorder |
Drug: Modafinil Drug: Nicotine Replacement Therapy |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Safety Study |
Official Title: | Modafinil and Nicotine in Adolescents: Phase I Trial |
Estimated Enrollment: | 100 |
Study Start Date: | June 2003 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
NRT is a critical part of treating nicotine withdrawal symptoms, such as cravings, sleeplessness, poor concentration, and anxiety. The addition of modafinil, a promising pharmacologic agent, may enhance the effectiveness of NRT by further reducing inattention and depressed mood. The purpose of this study is to examine the safety of using both modafinil and NRT in treating nicotine dependent adolescents. In addition, this study will examine the effects of modafinil and NRT, alone and in combination, on alleviating symptoms of inattention and depressed mood.
Participants in this 12-day dose escalation study will be tested under eight different dose conditions. Modafinil and NRT will first be tested alone; participants will be exposed to low doses prior to higher doses of medication. Various modafinil-NRT dose combinations will then be tested. Modafinil will be administered at 5 p.m. each day, and NRT will be self-administered at the start of each day in which a participant must complete lab tests. The following measures will be obtained at study visits occurring before and after the various modafinil-NRT dose combinations: nicotine withdrawal symptoms, medication side effects, activity level, cardiovascular response, and profile of mood states (POMS).
Ages Eligible for Study: | 16 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Catherine A. Martin, MD | 859-257-9341 | cmartin@uky.edu |
United States, Kentucky | |
University of Kentucky | Recruiting |
Lexington, Kentucky, United States, 40509 | |
Contact: Catherine Martin, MD 859-257-9341 cmartin@uky.edu | |
Principal Investigator: Catherine A. Martin, MD |
Study Chair: | Catherine Martin, PhD | University of Kentucky |
Responsible Party: | University of Kentucky ( Catherine A. Martin ) |
Study ID Numbers: | NIDA-15413, R03DA15413, DPMC |
Study First Received: | November 22, 2005 |
Last Updated: | September 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00258479 History of Changes |
Health Authority: | United States: Federal Government |
Nicotine Dependence Nicotine Use Disorder Tobacco Dependence |
Nicotine polacrilex Neurotransmitter Agents Tobacco Use Disorder Nicotinic Agonists Disorders of Environmental Origin Central Nervous System Stimulants Cholinergic Agents |
Neuroprotective Agents Modafinil Mental Disorders Nicotine Substance-Related Disorders Peripheral Nervous System Agents |
Nicotine polacrilex Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Agonists Tobacco Use Disorder Nicotinic Agonists Physiological Effects of Drugs Disorders of Environmental Origin Central Nervous System Stimulants Cholinergic Agents Protective Agents |
Neuroprotective Agents Modafinil Pharmacologic Actions Mental Disorders Nicotine Autonomic Agents Therapeutic Uses Substance-Related Disorders Ganglionic Stimulants Peripheral Nervous System Agents Central Nervous System Agents |